BioSpace News Archive

miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that on July 1, 2020 it received written notice from the Nasdaq Listing Qualifications Staff of the NASDAQ Stock Market LLC

Aditx Therapeutics, Inc. (Aditxt) (the “Company”) (Nasdaq: ADTX), a life sciences company developing technologies specifically focused on improving the health of the immune system through immune reprogramming and monitoring, today announced the closing of its previously announced $11.0 million initial public offering of 1,226,668 units, each unit consisting of one share of common stock

BD announced that it will conduct a live webcast of its third fiscal quarter 2020 earnings conference call on Thursday, August 6, 2020, at 8:00 a.m.

Senseonics Holdings, Inc. announced that it had made equity grants to new employees under its 2019 Inducement Plan in accordance with NYSE American Company Guide Section 711.

AmerisourceBergen Corporation (NYSE: ABC) today announced that it plans to release its results for the Third Quarter Fiscal 2020 on Wednesday, August 5, 2020, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on August 5, 2020. Participating in the conference call will be: Steven H. Collis, Chairman, President & Ch

Today, the U.S. Food and Drug Administration approved Rukobia (fostemsavir), a new type of antiretroviral medication for adults living with HIV who have tried multiple HIV medications and whose HIV infection cannot be successfully treated with other therapies because of resistance, intolerance or safety considerations. “This a

Assembly Biosciences, Inc. announced grants of stock options to ten new employees to purchase an aggregate of 112,600 shares of the Company’s common stock with an exercise price of $23.30 per share, the closing price of Assembly’s common stock on July 1, 2020.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Phase 3 trial of Kevzara ® (sarilumab) 400 mg in COVID-19 patients requiring mechanical ventilation did not meet its primary and key secondary endpoints when Kevzara was added to best supportive care compared to best supportive car

TerrAscend Corp. (CSE:TER) (OTCQX: TRSSF) (“TerrAscend” or the “Company”) today announced that its 2020 annual general meeting of shareholders (the “AGM”) will be held on August 18, 2020 . As a result of the ongoing impact of the COVID-19 pandemic and in accordance with continued public health measures, t

The U.S. Food and Drug Administration continued to take action in the ongoing response to the COVID-19 pandemic:.